OSR (NASDAQ:OSRH) Upgraded at Wall Street Zen

OSR (NASDAQ:OSRH) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of OSR in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

OSR Trading Up 16.4%

Shares of OSRH opened at $0.69 on Friday. The company has a market cap of $22.96 million, a price-to-earnings ratio of -0.54 and a beta of 0.59. OSR has a 1-year low of $0.38 and a 1-year high of $1.79. The company’s fifty day simple moving average is $0.49 and its 200 day simple moving average is $0.58.

Hedge Funds Weigh In On OSR

A hedge fund recently bought a new stake in OSR stock. Susquehanna International Group LLP acquired a new position in shares of OSR Holdings, Inc. (NASDAQ:OSRH) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned 0.37% of OSR at the end of the most recent reporting period. 55.30% of the stock is owned by hedge funds and other institutional investors.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.